Iversen, LL. Consideration of the cathinones, Advisory Council on the Misuse of Drugs, 31 Mar 2010. 286 kB.
Maheux, CR; Copeland, CR. Chemical analysis of two new designer drugs: Buphedrone and pentedrone. Drug Test. Anal., 1 Jan 2012, 4 (1), 17–23. 314 kB. https://doi.org/10.1002/dta.385
Zuba, D. Identification of cathinones and other active components of ‘legal highs’ by mass spectrometric methods. Trends Anal. Chem., 1 Feb 2012, 32, 15–30. 576 kB. https://doi.org/10.1016/j.trac.2011.09.009
Zuba, D; Byrska, B. Prevalence and co-existence of active components of ‘legal highs’. Drug Test. Anal., 1 Jun 2013, 5 (6), 420–429. 1.3 MB. https://doi.org/10.1002/dta.1365
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 1 Jan 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
EMCDDA. New drugs in Europe, 2010, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2011. 700 kB.
Jones, LE; Stewart, A; Peters, KL; McNaul, M; Speers, SJ; Fletcher, NC; Bell, SEJ. Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst, 25 Jan 2016, 141 (3), 902–909. 1.3 MB. https://doi.org/10.1039/c5an02326b
Vidal Giné, C; Espinosa, IF; Vilamala, MV. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Test. Anal., 1 Jul 2014, 6 (7-8), 819-824. 113 kB. https://doi.org/10.1002/dta.1610
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Fornal, E. Study of collision-induced dissociation of electrospray-generated protonated cathinones. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 705-715. 527 kB. https://doi.org/10.1002/dta.1573 #2
Nycz, JE; Malecki, G; Zawiazalec, M; Pazdziorek, T. X-ray structures and computational studies of several cathinones. J. Mol. Struct., 14 Sep 2011, 1002 (1), 10–18. 1.1 MB. https://doi.org/10.1016/j.molstruc.2011.06.030 #1e
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB.
Gaspar, H; Bronze, S; Oliveira, C; Victor, BL; Machuqueiro, M; Pacheco, R; Caldeira, MJ; Santos, S. Proactive response to tackle the threat of emerging drugs: Synthesis and toxicity evaluation of new cathinones. Forensic Sci. Int., 1 Sep 2018, 290, 146–156. 1.6 MB. https://doi.org/10.1016/j.forsciint.2018.07.001 #Buphedrone MS,NMR
Nagashima, M; Suzuki, J; Moriyasu, T; Yoshida, M; Shimizu, M; Hamano, T; Nakae, D. Analysis of uncontrolled drugs purchased in the fiscal year 2010. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2011, 62 99–105. 889 kB. #Buphedrone LC,MS,NMR,UV,other
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Cathinones Buphedrone
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #CA-003
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #P14 LC
Simmler, LD; Rickli, A; Hoener, MC; Liechti, ME. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology, 1 Apr 2014, 79, 152–160. 787 kB. https://doi.org/10.1016/j.neuropharm.2013.11.008 #Buphedrone